Journal of Thoracic Oncology

• 

  Publication Venue For

  • Chemotherapy at the End of Life (EOL) for Patients with Lung Cancer within the VA System.  10:S789-S790. 2015
  • Design, Execution, and Preliminary Biomarker Results from Paired Tumor Biopsy Cohorts of the AZD9291 AURA Trial.  10:S320-S320. 2015
  • Early-Stage Lung Cancer Treatment and Survival: Impact of Race.  10:S281-S281. 2015
  • HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer.  10:S296-S297. 2015
  • Impact of Radiation on Recurrence Patterns and Survival for Patients Undergoing Lobectomy for Stage IIIA-pN2 Non-Small Cell Lung Cancer.  10:S573-S573. 2015
  • Improved Survival in Patients with Stage I-II NSCLC Treated with Surgery or Radiotherapy in the Department of Veterans Affairs.  10:S280-S281. 2015
  • Long-Term Survival after Surgery for Pathologic N1 and N2 Small Cell Lung Cancer: A Comparison with Nonoperative Management.  10:S193-S194. 2015
  • PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504.  10:S401-S401. 2015
  • Survival after Surgery for pN1 and pN2 Small Cell Lung Cancer: A Comparison with Surgical Treatment of Non-Small Cell Lung Cancer.  10:S399-S400. 2015
  • Wedge Resection vs Segmentectomy for Patients with T1A N0 Non-Small Cell Lung Cancer.  10:S242-S242. 2015
  • WHEN IS A PATHOLOGICAL DIAGNOSIS PREFERRED BEFORE STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR STAGE I LUNG CANCER? A DECISION ANALYSIS.  9:S31-S31. 2014
  • SURGICAL TECHNIQUES AND RESULTS OF RECONSTRUCTION OF THE PULMONARY ARTERY FOR PATIENTS WITH CENTRAL NON-SMALL CELL LUNG CANCER.  8:S217-S217. 2013
  • VALIDATION OF THE CALGB AND EORTC PROGNOSTIC MODELS FOR MESOTHELIOMA BASED ON MULTIPLE CALGB TRIALS (ALLIANCE).  8:S934-S935. 2013
  • An Interim Report Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens..  7:S245-S246. 2012
  • Analysis of Prognostic Factors Affecting Local and Distant Recurrence Following Surgery for Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis.  7:S233-S234. 2012
  • 62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER.  6:S919-S920. 2011
  • OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406..  6:S447-S448. 2011
  • REPRODUCIBILITY OF INVASION IN PULMONARY ADENOCARCINOMA. AN INTERNATIONAL INTEROBSERVER STUDY.  6:S288-S289. 2011
  • Erratum: Extensive disease small cell lung cancer dose-response relationships: Implications for resistance mechanisms (Journal of Thoracic Oncology (2010) 5 (1826-1834)).  6:1281. 2011
  • Is Diabetes an Independent Risk Factor for Local Recurrence After Surgery for Non-small Cell Lung Cancer?.  5:S553-S553. 2010
  • Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms..  5:1826-1834. 2010
  • A Phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (SCLC): CALGB 30602.  4:S816-S817. 2009
  • A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.  4:S371-S372. 2009
  • Identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.  4:S522-S523. 2009
  • Implementation of IASLC revised staging system: imaging implications.  4:S16-S17. 2009
  • Pleural invasion.  4:S152-S153. 2009
  • The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: final analysis of CALGB 9761.  4:S576-S576. 2009
  • Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).  4:12-21. 2009
  • D5-01: Prognostic significance of molecular markers and clinical factors in stage ib non-small cell lung cancer (NSCLC): a laboratory companion study to CALGB 9633.  2:S403-S403. 2007
  • E01-02: State of the art mesothelioma diagnosis: a moving target.  2:S213-S214. 2007
  • E10-05: Comprehensive symptom management in advanced lung cancer.  2:S249-S250. 2007
  • An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): Maximizing the diagnostic procedure and the use of low-volume lung biopsies.  2:387-396. 2007
  • Erratum: Hibernoma: ¹⁸ F FDG PET/CT imaging (Journal of Thoracic Oncology (2007) 2, 6, (569-570)).  2:676. 2007
  • Erratum: Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment (Journal of Thoracic Oncology (2006) 1, (S20-S26)).  2:11. 2007
  • Molecular diagnostics in advanced NSCLC: Trying to maximize a non-ideal situation.  2:782-. 2007
  • Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment (vol 1, pg S 20, 2006).  2:11-11. 2007
  • Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care.  1:692-696. 2006
  • Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment.  1. 2006
  • Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors 2022
  • Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in EarlyStage Lung Cancer 2022
  • Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors 2022
  • The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival 2022
  • Factors Associated with Severe COVID-19 Infections in Lung Cancer Patients 2021
  • MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor 2021
  • Druggable Vulnerabilities in Therapy-Resistant Lung Cancers 2020
  • P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer 2019
  • Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRAS(G12C) Inhibitor, in Patients with Non-Small Cell Lung Cancer 2019
  • MA05.03 Impact of Time to Surgery on Outcomes in Patients Undergoing Outright Resection for Malignant Pleural Mesothelioma 2019
  • MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer 2019
  • OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC 2019
  • P1.16-13 Development of a Veterans Affairs Based Comprehensive Lung Cancer Survivorship Program 2019
  • P2.06-03 Timing of Surgery After Induction Therapy for Malignant Pleural Mesothelioma: A National Analysis 2019
  • MA27.06 Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA 2018
  • P1.16-50 The Role of Adjuvant Therapy for Patients with Early Stage Large Cell Neuroendocrine Lung Cancer: A National Analysis 2018
  • MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC 2017
  • ED06.04 Biology and Management of Tumor Cachexia 2017
  • MA06.10 A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC 2017
  • MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC) 2017
  • P2.03a-055 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials 2017
  • P3.03-036 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance) 2017
  • P3.04-013 The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma 2017
  • CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC 2016
  • Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review 2016
  • Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress 2016
  • 102P: Ablative robotic radiosurgery for inoperable patients with stage IA-IB non small cell lung cancer. 2016
  • Mechanism of Notch and Sox2 in Kras driven lung adenocarcinoma in type II cells∗ 2016
  • Cachexia 2015
  • Immunophenotyping of Circulating T Cells and TILs with Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer 2015
  • MD Anderson Oncology Expert Advisor (TM) System (OEA (TM)): A Cognitive Computing Recommendations Application (App) for Lung Cancer 2015
  • Epidermal Growth Factor Receptor (EGFR) Testing among Veterans Diagnosed with Lung Cancer 2015
  • A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB 2013
  • COMBINATION CHEMOTHERAPY AND AUTOPHAGY INHIBITION WITH HYDROXYCHLOROQUINE FOR ADVANCED NON-SMALL CELL LUNG CANCER 2013
  • EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG. 2013
  • LITHIUM AS A NEUROPROTECTIVE AGENT IN PATIENTS UNDERGOING PROPHYLACTIC CRANIAL IRRADIATION (PCI) FOR SMALL CELL LUNG CANCER (SCLC): THE TULIP STUDY 2013
  • RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC. 2013
  • THE ADDITION OF ANTI-ANGIOGENIC TYROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS 2013
  • Retrospective Analysis Of The Impact Of Age On Overall Survival In Patients With Non-small Cell Lung Cancer 2012
  • BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER 2011
  • CASE PRESENTATION: SMALL T1 SUBPLEURAL LUNG LESION IN THE RIGHT UPPER LOBE, INCIDENTALLY FOUND 2011
  • INDUCTION CHEMORADIOTHERAPY IS NOT SUPERIOR TO INDUCTION CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE IIIA(N2) NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS 2011
  • NEIGHBORHOOD-LEVEL SOCIOECONOMIC (SES) DETERMINANTS NEGATIVELY IMPACT TREATMENT DECISIONS AMONG NON-SMALL CELL LUNG CANCER PATIENTS IN THE SOUTHEASTERN UNITED STATES 2011
  • PERSISTENT N2 DISEASE AFTER NEOADJUVANT CHEMOTHERAPY-NOW WHAT? 2011
  • TALACTOFERRIN ALFA (TLF) REDUCES MORTALITY ACROSS A BROAD RANGE OF PATIENTS WITH SEVERE SEPSIS 2011
  • VALIDATION OF A QPCR-BASED GENETIC ASSAY PROGNOSTIC OF SURVIVAL IN RESECTED NON-SMALL CELL LUNG CANCER 2011
  • Survival Among Smokers and Nonsmokers in the National Comprehensive Cancer Network (NCCN) Non-small Cell Lung Cancer (NSCLC) Cohort 2010
  • KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies 2009
  • Management of myelosuppression in the lung cancer patient 2009
  • Measurement of gene expression biomarkers by qNPA (TM) from archived NSCLC FFPE: prognosis of 5-year survival 2009
  • Ribonucleotide reductase (RRM1) expression in non-small cell lung cancer (NSCLC): implications for personalizing gemcitabine-based therapy 2009
  • Socioeconomic status predicts outcomes from NSCLC 2009
  • Techniques of VATS resections for lobectomy, segmentectomies, and lymph node dissections and their results in 2009: who are the candidates, when do you not do this? 2009
  • Thymidylate synthase (TS) RNA expression in non-small cell lung cancer (NSCLC): implications for personalizing pemetrexed therapy 2009
  • Radiographic Imaging of Bronchioloalveolar Carcinoma: Screening, Patterns of Presentation and Response Assessment 2006